Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-110 for pain from knee osteoarthritis
NL-OMON37475Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Hu-alphaD11 in osteoarthritis (OA) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Subject's Assessment of Arthritis Pain Intensity, WOMAC and 5 more. Planned start Oct 2011; status: withdrawn.
02
Drugs
Hu-alphaD11
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON37475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37475.